US2010068257A1PendingUtilityA1
Sustained Release of Antiinfectives
Est. expiryOct 29, 2022(expired)· nominal 20-yr term from priority
A61P 31/00A61K 9/0078Y10S977/906A61K 31/7036A61K 31/496A61K 31/545A61K 31/407A61K 9/127Y10S977/773Y10S977/907A61K 9/0073A61K 9/48Y02A50/30
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
Claims
exact text as granted — not AI-modified1 . A method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
2 . The method of treating or ameliorating of claim 1 , wherein the antiinfective is an aminoglycoside, a tetracycline, a sulfonamide, para-aminobenzoic acid, a diaminopyrimidine, a quinolone, a beta-lactam, a beta-lactam and a beta-lactamase inhibitor, chloramphenicol, a macrolide, lincomycin, clindamycin, spectinomycin, polymyxin B, colistin, vancomycin, bacitracin, isoniazid, rifampin, ethambutol, ethionamide, aminosalicylic acid, cycloserine, capreomycin, a sulfone, clofazimine, thalidomide, or combination thereof.
3 . The method of treating or ameliorating of claim 1 , wherein the antiinfective is a polyene antifungal, flucytosine, imidazole, triazole, griseofulvin, terconazole, butoconazole ciclopirax, ciclopirox olamine, haloprogin, tolnaftate, naftifine, terbinafine, or combination thereof.
4 . The method of treating or ameliorating of claim 1 , wherein the antiinfective is an aminoglycoside.
5 . The method of treating or ameliorating of claim 4 , wherein the administrated amount is 100 mg or less for every day of treatment or amelioration.
6 . The method of treating or ameliorating of claim 5 , wherein the dosing is once a day or less.
7 . The method of treating or ameliorating of claim 5 , wherein the dosing is once every two days or less.
8 . The method of treating or ameliorating of claim 5 , wherein the dosing is once every three days or less.
9 . The method of treating or ameliorating of claim 1 , wherein the antiinfective is amikacin.
10 . The method of treating or ameliorating of claim 9 , wherein the administrated amount is 100 mg or less for every day of treatment or amelioration.
11 . The method of treating or ameliorating of claim 10 , wherein the dosing is once a day or less.
12 . The method of treating or ameliorating of claim 10 , wherein the dosing is once every two days or less.
13 . The method of treating or ameliorating of claim 10 , wherein the dosing is once every three days or less.
14 . The method of treating or ameliorating of claim 1 , wherein the infection to be treated or ameliorated is a pseudomonas (e.g., P. aeruginosa, P. paucimobilis, P. putida, P. fluorescens, and P. acidovorans ), staphylococcal, Methicillin-resistant Staphylococcus aureus (MRSA), streptococcal (including by Streptococcus pneumoniae ), Escherichia coli, Klebsiella, Enterobacter, Serratia, Haemophilus, Yersinia pestis, Burkholderia pseudomallei, B. cepacia, B. gladioli, B. multivorans, B. vietnamiensis, Mycobacterium tuberculosis, M. avium complex (MAC) ( M. avium and M. intracellulare ), M. kansasii, M. xenopi, M. marinum, M. ulcerans, or M. fortuitum complex ( M. fortuitum and M. chelonei ) infection.
15 . The method of treating or ameliorating of claim 1 , wherein the infection to be treated or ameliorated is a pseudomonas infection.
16 . The method of treating or ameliorating of claim 1 , wherein the infection to be treated or ameliorated is a P. aeruginosa infection.
17 . The method of treating or ameliorating of claim 1 , wherein the administrated amount is 50% or less of the comparative free drug amount
18 . The method of treating or ameliorating of claim 17 , wherein the dosing is once a day or less.
19 . The method of treating or ameliorating of claim 17 , wherein the dosing is once every two days or less.
20 . The method of treating or ameliorating of claim 17 , wherein the dosing is once every three days or less.
21 . The method of treating or ameliorating of claim 1 , wherein the administrated amount is 35% or less of the comparative free drug amount.
22 . The method of treating or ameliorating of claim 1 , wherein the administrated amount is 20% or less of the comparative free drug amount.
23 . The method of treating or ameliorating of claim 1 , wherein the administrated amount is 10% or less of the comparative free drug amount.
24 . The method of treating or ameliorating of claim 1 , wherein the effective amount is one effective to treat or ameliorate after symptoms of lung infection have arisen
25 . A method of treating or ameliorating pulmonary infection in an animal comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, and (ii) the dosing is once every two days or less.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.